Acadia Pharmaceuticals | ACAD - Trade Creditors


Acadia Pharmaceuticals reported $12.25M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
ALKERMES USD 102.36M 5.59M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Cara Therapeutics USD 3.22M 859K Dec/2025
Corcept Therapeutics USD 33.31M 7.14M Mar/2026
Cytokinetics USD 24.71M 80.91M Mar/2026
Eisai JPY 75.89B 9.6B Mar/2026
Eli Lilly USD 5.03B 350M Mar/2026
Incyte USD 228.62M 1.41B Mar/2026
J&J USD 10.46B 1.53B Mar/2026
Moderna USD 161M 156M Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
Prothena USD 4.3M 1.58M Mar/2026
PTC Therapeutics USD 25.48M 20M Mar/2026
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026